| GeneLibs

题目:: [Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
作者:: Fujimi(Akihito),Hashimoto(Akari),Kanisawa(Yuji),Okuda(Toshinori),Minami(Shinya),Doi(Tadashi),Matsuno(Teppei),Ishikawa(Kazuma),Uemura(Naoki)
状态:: 发布时间2013-03-08 , 更新时间 2015-11-19
期刊:: Rinsho Ketsueki
摘要:: A 69-year-old male was referred to our hospital because of anemia, renal insufficiency, and a positive urine test for Bence-Jones protein. A bone marrow examination showed 73.7% of myeloma cells with lymphoplasmacytic morphology, the strong expressions of CD20 and CD23 by flow cytometry, and the chromosomal aberration of CCND1/IGH by FISH analysis. He was diagnosed with multiple myeloma, IgG-λ type. The initial treatment with bortezomib plus dexamethasone (BD) provided a rapid decrease in the level of IgG; however, he developed bortezomib-induced recurrent paralytic ileus accompanied by aspiration pneumonia during the second course. Interestingly, CD23 expression on myeloma cells decreased from 87.7% to 2.2% after 2 courses of BD. Negative CD23 expression was maintained following lenalidomide plus dexamethasone therapy. There are extremely few reports on CD23 expression on myeloma cells, and this is the first case report of multiple myeloma in which CD23 expression was lost after BD therapy.
语言:: jpn
DOI:

文献库文献相关信息